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Summary
This update on plasma cell myeloma has been elaborated
by a Swiss expert panel as a result of the plethora of new
data on the treatment of plasma cell myeloma reported re-
cently. It adds new insights to the more extensive review
that was published 3 years ago and may help clinicians on
decision making for their patients. The new recommenda-
tions for distinguishing plasma cell myeloma from smoul-
dering myeloma are briefly presented, including a section
on contemporary imaging studies with this respect. For-
mer panel recommendations that remain unchanged by
new results will not be discussed in detail as the major fo-
cus of this review is on treatment-relevant new develop-
ments.
Keywords: plasma cell myeloma, multiple myeloma, pro-
teasome inhibitors, IMIDs, monoclonal antibodies, stem
cell transplantation
Introduction
This update on plasma cell myeloma has been elaborated
by a Swiss expert panel as a result of the plethora of new
data on the treatment of plasma cell myeloma reported re-
cently. It adds new insights to the more extensive review
that was published three years ago and may help clinicians
on decision making for their patients [1]. The new recom-
mendations for distinction of plasma cell myeloma from
smouldering myeloma are briefly presented, including a
section on contemporary imaging studies with this respect.
Former panel recommendations that remain unchanged by
new results will not be discussed in detail as the major fo-
cus of this review is on treatment-relevant new develop-
ments.
Updated diagnostic criteria
Monoclonal gammopathy of undetermined signifi-
cance
The definition of monoclonal gammopathy of undeter-
mined significance (MGUS) has not changed. Patients
need to have less than 30 g/l serum M-protein, less than
10% clonal plasma cells in the bone marrow, and no end-
organ damage for this diagnosis. Patients with im-
munoglobulin M (IgM) MGUS and non-IgM MGUS differ
in terms of progression risk. With the two laboratory para-
meters M-protein (<15 g/l versus ≥15 g/l) and serum free
light chain (FLC) ratio (normal versus pathological), three
risk categories can be distinguished for IgM and non-IgM
MGUS enabling a risk adapted patient monitoring [2]. As
of today, no data are available supporting treatment of pa-
tients with MGUS.
Smouldering myeloma or plasma cell myeloma?
The diagnosis of a myeloma demands the presence of a
serum M-protein of ≥30 g/l and/or ≥10% of clonal plasma
cells in the bone marrow. Asymptomatic patients without
myeloma-defining events have a so-called smouldering
myeloma, which may progress to a symptomatic plasma
cell myeloma over time. The risk of progression can be es-
timated, as for MGUS, by the presence of various risk fac-
tors, which facilitate an individualised patient monitoring
[3, 4]. A few years ago, a randomised trial evaluated the
impact of early treatment in patients with high-risk smoul-
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dering myeloma with lenalidomide and dexamethasone,
as compared with observation, and showed improved pro-
gression-free survival (PFS) and overall survival (OS) with
early treatment [5]. However, it was a rather small study,
with 125 treated patients, and the specified risk factors are
not used commonly for risk stratification. Therefore, this
early treatment approach cannot be generally recommend-
ed until additional data are available to further support it.
The presence of end organ damages, primarily the so-
called CRAB-criteria (hypercalcaemia, renal failure,
anaemia, bone disease), define an underlying plasma cell
myeloma in need of therapy. In the most recent update of
the criteria for diagnosis of plasma cell myeloma, three
additional myeloma-defining events have been introduced
to discriminate symptomatic myeloma without evidence of
classical end-organ damage from smouldering myeloma:
clonal plasma cells of 60% or greater in the bone marrow,
a serum FLC ratio of 100 or greater, or more than one fo-
cal lesion larger than 5 mm on magnetic resonance imag-
ing (MRI) [6]. The reason for incorporation of these three
new biomarkers of malignancy is that each one was found
to constitute an “ultrahigh” risk of progression to sympto-
matic disease within two years of greater than 70–80%. To
address these additional myeloma defining events, the term
“SLiM-CRAB” (SLiM: S=sixty; Li=light chain; M=MRI)
was coined soon after publication of the updated criteria.
The new definitions of smouldering and symptomatic plas-
ma cell myeloma are shown in table 1.
Imaging
Imaging has become an increasingly important tool for the
precise staging of the patients. The use of “native” whole-
body computed tomography of the bone can be considered
standard of care in daily practice. Importantly, this tech-
nique has sufficient sensitivity for the detection of small
bone defects and the use of a contrast agent can be avoid-
ed in most cases. As mentioned above, whole-body MRI
needs to be considered in asymptomatic patients with new-
ly diagnosed myeloma without other underlying myelo-
ma defining events to search for occult focal lesions. An
18fluorodeoxyglucose (18F-FDG) positron emission tomog-
raphy combined with a CT (PET/CT) may be performed
optionally for specific indications. It has high sensitivity
and specificity for the detection of extramedullary disease,
and in patients with suspected solitary plasmacytoma it is
a mandatory alternative to whole body MRI to confirm this
diagnosis or to detect underlying occult lesions. In addi-
tion, it may develop into a helpful tool to assess response
to treatment and minimal residual disease (MRD), but this
scope of application cannot be considered standard yet [7].
Risk stratification
A few years ago, the International Staging System (ISS),
a simple prognostic stratification tool using albumin and
beta-2 microglobulin concentrations in serum, which had
been introduced more than a decade ago, was revised by
the IMWG [8]. The new revised ISS (R-ISS) includes two
additional parameters, the presence of chromosomal high
risk abnormalities, and an elevated serum lactate dehydro-
genase (LDH) value, which both have been identified as
risk factors in a pooled analysis of almost 4500 patients en-
rolled into 11 international trials. By using this new strat-
ification tool patients with newly diagnosed plasma cell
myeloma may be assessed reliably in terms of the relative
risk for their survival (table 2) [9].
First-line treatment
Patients need to be evaluated for their eligibility to undergo
high dose therapy with melphalan followed by autologous
Table 1: Adapted from Rajkumar et al. [6].
Definition of plasma cell myeloma
Clonal plasma cells in the bone marrow ≥ 10% or biopsy proven osseous or extramedullary plasmacytoma
and ≥1 of the following SLiM-CRAB-criteria
• Ultrahigh risk biomarker for malignancy
o (S) sixty % or greater clonal plasma cells in the bone marrow
o (Li) light chain ratio of involved to not involved FLC ≥100 (involved free light chain must be at least 100mg/l)
o (M) more than 1 focal lesion in MRI study (≥5 mm)
• End organ damage, attributed to the underlying disease
o (C) hypercalcaemia >0.25 mmol/l above the upper limit of normal or >2.75 mmol/l
o (R) renal insufficiency: creatinine clearance <40 ml/min or serum creatinine >177 μmol/l
o (A) anaemia: Hb >20g/l below the lower limit of normal or <100 g/l
o (B) bone lesions: ≥1 osteolytic lesion on radiography, CT or PET-CT
Definition of smouldering myeloma
The following criteria must be fulfilled
• Serum M-protein (IgG or IgA) ≥30 g/l or M-protein in urine ≥500 mg/24h and/or clonal plasma cells in the bone marrow of 10–60%
• no myeloma defining events or amyloidosis present
FLC = free light chains; MRI = magnet resonance imaging; Hb = haemoglobin; CT = computed tomography; PET-CT = positron emission tomography-computed tomography; IgG
= immunoglobulin G; IgA = immunoglobulin A
Table 2: The revised international staging system (R-ISS) [9].
Stage I (28%) Stage II (62%) Stage III (10%)
ISS I and
no high risk cytogenetics* and
normal LDH
Neither Stage I nor Stage III ISS III plus either
High risk cytogenetics* or
elevated LDH
5 -year OS 82%
5-year PFS 55%
5 -year OS 62%
5-year PFS 36%
5 -year OS 40%
5-year PFS 24%
ISS = international staging system; LDH = lactate dehydrogenase; OS = overall survival; PFS = progression-free survival; FISH = fluorescence in situ hybridisation * High risk
abnormalities: del(17p) and/or t (4, 14) and/or t(14:16), as tested by FISH.
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stem cell transplantation (HDT/ASCT), which is still con-
sidered standard of care for the younger patients.
Transplant-eligible patients
A few years ago, a randomised trial confirmed the value of
HDT/ASCT even in the era of new myeloma drugs [10].
However, this study used lenalidomide and dexamethasone
(RD) for induction, which is nowadays considered less
efficacious than triple regimens commonly used in clini-
cal practice today. In this trial consolidation consisted of
a double autologous transplant, and lenalidomide mainte-
nance was given until progression. In the recently pub-
lished French IFM2009 trial patients received bortezomib,
lenalidomide and dexamethasone (VRD) as first line treat-
ment, and they received either an intensification with high-
dose chemotherapy with melphalan and autologous stem
cell support, followed by two additional cycles of VRD
as further consolidation, or they received eight cycles of
VRD alone. All patients were assigned to receive lenalido-
mide as maintenance for one year. The administration of
high-dose melphalan resulted in a significantly improved
progression-free survival compared with the conventional
treatment with bortezomib, lenalidomide and dexametha-
sone alone (50 vs 36 months; hazard ratio [HR] 0.65, p
<0.001). However, no benefit in OS was observed so far
and the authors concluded that high-dose chemotherapy
may well be postponed to later salvage treatment to secure
long-term survival [11]. A further trial, SWOG S0777, also
evaluated VRD as first line treatment in patients not in-
tended to undergo immediate high-dose chemotherapy. Af-
ter eight cycles of VRD, patients continued with lenalido-
mide and dexamethasone as maintenance treatment until
progression. The VRD triple therapy was compared with
lenalidomide and dexamethasone alone and resulted in a
significant increase of both PFS and OS [12].
Very recently, the large, international EMN02/HOVON95
trial assessed the value of one or two HDT/ASCTs as inten-
sification after induction with the triple combination borte-
zomib, cyclophosphamide and dexamethasone (VCD)
compared with a conventionally dosed treatment with
bortezomib, melphalan and prednisone (VMP) after VCD
induction. In addition, the study also assessed the efficacy
of a short consolidation with two cycles of VRD. The treat-
ment arm with HDT/ASCT and the use of VRD as a short
consolidation resulted in an improved PFS compared with
the conventional treatment arm with VCD, followed by
VMP [13, 14]. Furthermore, in a more recent analysis, the
use of a tandem HDT/ASCT improved PFS and OS in the
overall patient population and particularly in patients with
high risk disease [15].
These results are in contrast to a study evaluating the role
of consolidation treatment after HDT/ASCT that has re-
cently been published (StaMINA trial). In this US trial,
after induction treatment whose duration and composition
were left to the investigator, and a subsequent HDT/ASCT,
patients were randomised to receive a second HDT/ASCT,
four cycles of VRD, or no consolidation at all. All patients
went on to receive lenalidomide maintenance until pro-
gression. After a follow-up of 38 months, no differences
in PFS or OS were seen in this study. Although not pre-
defined, most patients (> 50%) received four to ten cycles
of VRD as a long induction, suggesting that a highly ef-
ficacious upfront treatment may render further consolida-
tive treatment options unnecessary in unselected patients.
In addition, the length of induction treatment prior to HDT/
ASCT was not defined and sometimes even extended up to
12 months, making it very difficult to compare this study
with other trials that were more structured and concise re-
garding number of induction cycles [16].
Based on all these data, the combination of bortezomib,
lenalidomide and dexamethasone should be considered the
preferred first-line treatment for transplant-eligible pa-
tients. By administering VRD upfront in transplant-eligible
patients, the need for further consolidation strategies after
HDT/ASCT may be diminished, especially in standard risk
patient. More intense treatment with further consolidation
or tandem transplantation, based on the underlying risk
factors, should be considered especially in high-risk pa-
tients.
As depth of response indicated by minimal residual disease
(MRD), and time to next treatment (TTNT) are reliable
indicators for the prognosis of the patients, HDT/ASCT
should remain part of the first-line treatment strategy for
younger and/or fit patients, although the lack of OS benefit
may suggest that deferral until relapse may achieve compa-
rable long term survival. Standardised assessment of MRD
may help to select patients for whom immediate HDT/AS-
CT is not necessary in the near future, but this technology
has not yet been established for daily practice [17].
With respect to maintenance treatment after HDT/ASCT,
the data of three randomised studies (CALGB 100104,
GIMEMA RV-MM-PI-209, IFM 2005-02) have been in-
cluded in a meta-analysis published recently, which con-
firmed an OS benefit for the treatment with lenalidomide
after a longer follow-up [18]. It has to be taken into ac-
count that the OS benefit observed was not significant in
the subgroups of patients with elevated LDH and renal fail-
ure.
The UK Myeloma XI trial of a response- and immunomod-
ulatory drug (IMID)-based induction with the addition of
bortezomib in the event of an inadequate response to cy-
clophosphamide, thalidomide, dexamethasone (CTD) or
cyclophosphamide, lenalidomide, dexamethasone (CRD),
demonstrated the ability of lenalidomide to improve PFS
and OS across all subgroups of patients when given as
maintenance, even in patients with poor risk cytogenetics
[19]. The optimal duration of the maintenance treatment
needs further elaboration. The German group suggests,
based on their GMMG-MM5 trial, that in the upfront au-
tologous transplant setting the administration of lenalido-
mide for two years has a superior outcome in terms of
OS compared with a treatment until complete remission,
whereas PFS is not significantly prolonged [20]. There-
fore, based on the available data, lenalidomide mainte-
nance after HDT/ASCT for at least two years is nowadays
considered standard of care for the majority of patients.
The question of the duration of lenalidomide maintenance
may hopefully be answered definitely by the still ongoing
Determination trial, which is using lenalidomide mainte-
nance until progression.
Two randomised phase III studies have investigated the
efficacy of a proteasome inhibitor for maintenance treat-
ment. In the HOVON-65/GMMG-HD4 trial patients were
treated with thalidomide or bortezomib maintenance for
Review article: Biomedical intelligence Swiss Med Wkly. 2019;149:w20031
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 8
two years, and in the TOURMALINE-MM3 study patients
received ixazomib or placebo for two years. In both trials,
patients with high risk cytogenetics seem to have benefit-
ted most from the proteasome inhibitor, which may thus be
considered as a reasonable alternative to lenalidomide for
selected patients [21, 22].
Transplant-ineligible patients
Based on the results of the aforementioned study SWOG
0777, in which HDT/ASCT was not a mandatory part
of the protocol, VRD can also be considered a treatment
option for patients not eligible for transplantation but fit
enough to tolerate multi-agent regimens. As higher rates
of adverse events have to be anticipated with VRD than
with RD alone, older patients and patients with comorbidi-
ties need to be selected carefully for this treatment regi-
men. From a practical point of view, the triple combination
may be better tolerated by elderly patients if appropri-
ate dose modifications are made (“VRD-lite”) [23]. The
“classic” combination of bortezomib, melphalan and pred-
nisone (VMP) can still be considered a treatment option
with a predictable risk profile, particularly if IMIDs are
contraindicated or not tolerated. The addition of the mon-
oclonal CD38 antibody daratumumab to VMP as standard
first-line treatment in the phase III ALCYONE trial result-
ed in a dramatic improvement of PFS and response rates,
suggesting that this antibody-containing quadruple combi-
nation may be an emerging treatment option for elderly pa-
tients not eligible for transplantation [24]. Very recently,
the addition of daratumumab to RD has also been shown
to improve PFS markedly compared with RD alone in the
randomised phase III MAIA study, making this an addi-
tional future first-line treatment option for transplant-inel-
igible patients [25]. However, both combinations are not
yet approved in Switzerland and since the anti-CD38 an-
tibody also targets normal plasma cells, the rates of infec-
tious complications may be of concern in this vulnerable
population.
For older and frail patients, the RD combination can be
considered a valuable alternative first-line option, but du-
ration of treatment remains a matter of debate. In the up-
dated survival analysis of the FIRST trial, the improve-
ments of PFS and OS were confirmed for lenalidomide
and dexamethasone given continuously compared with the
old standard combination of melphalan, prednisone and
thalidomide (MPT). In patients achieving complete or very
good partial responses, continuous RD achieved a
30-month longer median time to next treatment compared
with Rd for 18 months (69.5 vs 39.9 months). Based on
these data, RD treatment may be preferably continued until
progression, particularly in patients who tolerate it well
and who achieve a deep remission [26, 27]. Furthermore,
the combination of bortezomib and dexamethasone may
also be considered a valuable alternative for this patient
group, particularly in frail patients or patients with renal
impairment [28]. Unfortunately, we do not have trials com-
paring VMP with RD as first-line treatment of elderly pa-
tients and since both regimens are approved, choice of
treatment is based on patient preference, comorbidities and
fitness. A recent post hoc comparison of two studies
showed that transplant-ineligible patients with high risk
cytogenetics and patients aged <75 years may derive more
benefit from bortezomib-based induction treatment than
with lenalidomide-based treatment [29].
Later line treatment
Patients with progression of their plasma cell disease may
need further effective treatment at some point. Disease pro-
gression alone may not necessarily demand immediate re-
treatment. When to start a new treatment is dependent on
various factors and needs to be addressed individually. The
European Myeloma Network provided criteria for relapse
and retreatment, which are helpful for daily practice [30].
Briefly, patients with new or worsening SLiM-CRAB cri-
teria and patients with highly aggressive disease at diag-
nosis or a short treatment interval should start with a new
treatment immediately. Patients with a sole biochemical re-
lapse may be treated in the event of a short doubling time
of the serum M-protein or a significant and continuous in-
crease of M-protein or serum free light chains within a
time period of up to two months. Significant progress in
the treatment of second or later lines has been made dur-
ing recent years, with the approval of six new antimyeloma
agents in the US and Europe, and in part also in Switzer-
land. Two next generation proteasome inhibitors with a dif-
ferent toxicity profile from bortezomib were made avail-
able. Carfilzomib (K) and ixazomib (I) when combined
with lenalidomide and dexamethasone (KRD or IRD, re-
spectively) resulted in improved PFS compared with the
standard double therapy [31, 32]. Carfilzomib is the first
of the next generation agents that has been shown to im-
prove OS compared with the respective comparator arms
in the relapsed setting after appropriate follow up [33, 34].
Carfilzomib is administered twice weekly intravenously
(at a dose of 27 mg/m2) combined with lenalidomide and
dexamethasone. Carfilzomib was also approved in combi-
nation with dexamethasone alone at a higher dose of 56
mg/m2 (KD), which resulted in improved OS compared
with bortezomib and dexamethasone (VD) in the relapsed
setting. Recently, concerns have been raised about the car-
diac safety of higher doses of carfilzomib. In general, the
drug should preferentially be administered to patients with
normal cardiac function, with no underlying severe cardiac
comorbidities and only in the case of an optimal control
of arterial blood pressure. In contrast to carfilzomib, ix-
azomib is taken orally once per week, allowing an all-
oral combination with lenalidomide and dexamethasone
(IRD). Of note, the TOURMALINE-MM1 trial is the only
placebo-controlled phase III trial in this setting. The main
toxicities are rash and gastrointestinal disturbances. The
carfilzomib combinations, either KRD or KD, and IRD are
approved in Switzerland and readily available for patients
with relapsed disease.
Two monoclonal antibodies have been approved in recent
years. Elotuzumab targets the surface antigen SLAMF7
(CD319), which is expressed on clonal plasma cells, in-
ducing an antibody-dependent cellular cytotoxicity. In ad-
dition, natural killer cells also express this antigen and may
be activated by antibody binding. These modes of action
result in an improvement of PFS and, at the 4-year update,
also of OS (48 vs 40 months), when elotuzumab is com-
bined with RD after at least one previous treatment line in
patients not refractory to lenalidomide. The Eloquent-2 tri-
al has not revealed any particular safety concerns [35]. In-
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fusion reactions are rare and the infusion duration much
more convenient than for the second available antibody,
daratumumab, which targets the CD38 antigen on plasma
cells. Like elotuzumab, daratumumab has an additional,
immunological mode of action. The target antigen CD38
is also expressed on normal plasma cells and regulatory T
cells, which may be depleted during daratumumab thera-
py. About half of the patients have mild to moderate reac-
tions during the first daratumumab infusion. Since CD38
is also expressed on the smooth muscle cells of the air-
ways, patients with a severe chronic obstructive pulmonary
disease or severe asthma might not qualify for this anti-
body. Daratumumab monotherapy achieves response rates
of over 30% in heavily pretreated patients and has been
approved in this setting [36]. Recently, the results of two
large randomised twin-studies (CASTOR and POLLUX)
have been published, in which daratumumab was com-
bined with either bortezomib and dexamethasone (CAS-
TOR) or lenalidomide and dexamethasone (POLLUX).
Both double regimens served as comparators in the stan-
dard arms of the two studies. PFS was markedly improved
by the addition of the monoclonal antibody and the PFS2
curves of both trials were shown to favour the investiga-
tional arm [37, 38]. Daratumumab recently obtained ap-
proval by the US Food and Drug Administration in com-
bination with pomalidomide and dexamethasone for the
treatment in the relapsed-refractory setting [39].
The third-generation IMID pomalidomide, in combination
with dexamethasone, was approved four years ago after at
least two previous treatment lines, including a proteasome
inhibitor and an IMID, as it offers clinically meaningful
benefit in terms of response and survival rates [40]. Re-
cently, the addition of elotuzumab to pomalidomide and
dexamethasone resulted in a significantly improved PFS
with a strong preliminary signal also for an OS benefit,
making this a future standard treatment for patients who
are double refractory to an IMID and a proteasome in-
hibitor [41].
The histone deacetylase (HDAC) inhibitor panobinostat
received a first-in-class approval in combination with
bortezomib and dexamethasone for treatment of patients
after at least two previous regimens, including a protea-
some inhibitor and an IMID, who are not refractory to
bortezomib [42]. However, panobinostat is not frequently
used for myeloma treatment in Switzerland.
Based on the results discussed here, various new treatment
options are available for patients with relapsed multiple
myeloma. The choice of treatment depends on disease-
and patient-related factors: the number and composition
of previous treatment regimens, the tolerability of and re-
sponse to previous treatments, underlying comorbidities,
age and, last but not least, the preferences of the patient.
Patients with a long-lasting response of more than 12–18
months may be retreated with the same regimen as in
first line. However, patients with a shorter duration of re-
sponse should receive alternative regimens. In addition,
transplant-eligible patients may also undergo salvage-AS-
CT in the event of a remission duration of more than 18–24
months, based on the data available today. Allogeneic stem
cell transplantation may be considered only in young high-
risk patients who relapsed shortly after primary treatment
with an effective induction treatment and subsequent AS-
CT, and should be ideally carried out in the context of a
clinical trial [43]. A possible algorithm for first and later
line treatment is depicted in figure 1.
Additional treatment
All patients with newly diagnosed plasma cell myeloma
should receive additional antiresorptive therapy with zole-
dronic acid, since rates of skeletal events and survival may
be favourably affected [44]. A recently published noninfe-
riority trial compared the administration of zoledronic acid
every 12 weeks with the standard 4-week administration
and found no differences in terms of time to next skeletal
event between the two arms. The 12-weekly administration
of zoledronic acid may thus be an alternative to the month-
ly administration routine [45]. The monoclonal antibody
denosumab is a receptor activator of NF-κB (RANK)-lig-
and inhibitor and approved for treatment of patients who
have osteoporosis or bone metastases of solid tumours
and are receiving chemotherapy. Based on newly available
positive data from a placebo-controlled noninferiority trial
comparing 120 mg denosumab subcutaneously with 4 mg
zoledronic acid intravenously, both given every 4 weeks,
this drug might be an option, especially for patients with
renal failure, underlying intolerance of or contraindications
to zoledronic acid. Denosumab received FDA approval on
5 January 2018, but as it is not yet approved in Switzer-
land, reimbursement of the treatment costs by the health
insurance company needs to be assured beforehand [46].
Bullet points
– High dose chemotherapy (HDT) with subsequent autol-
ogous stem cell transplantation (ASCT) can still be con-
sidered standard of care for eligible patients in the first-
line setting as it achieves deeper responses, although
study data suggest that deferral until relapse may
achieve comparable long-term survival
– The combination of bortezomib, lenalidomide and dex-
amethasone (VRD) can be considered the preferred reg-
imen for first-line treatment in transplant-eligible pa-
tients, and is an option in fit, transplant-ineligible
patients.
– Maintenance treatment with lenalidomide for at least
two years may be considered standard of care for the
majority of patients after HDT/ASCT.
– Additional options such as consolidation treatment
(e.g., two VRD cycles after HDT/ASCT) or second
(tandem) transplantation should be based on the pa-
tient´s individual risk profile and response to the first
HDT/ASCT. Patients with high-risk cytogenetics
should be considered for tandem transplantation.
– The combinations of the monoclonal anti-CD38 anti-
body daratumumab with bortezomib, melphalan and
prednisone (D-VMP) or with lenalidomide and dexam-
ethasone (DRD) may evolve as new first-line treatment
options for older, transplant-ineligible patients able to
undergo multi-agent therapy.
– Lenalidomide and dexamethasone (RD) improves pro-
gression-free (PFS) and overall survival (OS) in elderly
patients with newly diagnosed plasma cell myeloma
and should be considered standard of care.
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Figure 1: Treatment algorithm for first and later lines in patients, according to their eligibility for autologous stem cell transplantation. ASCT =
autologous stem cell transplantation; VGPR = very good partial remission; Len = lenalidomide = PI = proteasome inhibitor; IMID = im-
munomodulatory drug; Dexa = dexamethasone; PFS = progression-free survival
– Various new treatment options have become available
for second or later lines, and the choice of the best regi-
men needs to be based upon previous treatment regi-
mens, toxicity profile, comorbidities and preference of
each patient.
– The daratumumab in combination with dexamethasone
and either lenalidomide (DRD) or bortezomib (DVD)
results in substantial improvement of PFS in patients
with relapsed multiple myeloma.
– Carfilzomib, ixazomib, or the monoclonal anti-
SLAMF7 antibody elotuzumab in combination with
lenalidomide and dexamethasone are additional effec-
tive second line treatment options. Panobinostat may be
considered in combination with bortezomib and dexam-
ethasone but is less frequently used.
– Patients treated with at least two previous lines, includ-
ing an immunomodulatory drug (IMID) and a protea-
some inhibitor, may be treated with the triple combina-
tion of elotuzumab, pomalidomide and dexamethasone
as third line treatment.
– Daratumumab monotherapy may achieve response rates
of over 30% in patients pretreated with at least two pre-
vious lines and is currently being used as third- or
fourth-line treatment.
– The RANK-ligand inhibitor denosumab can be consid-
ered an equally effective alternative to zoledronic acid
as antiresorptive treatment in patients with newly diag-
nosed plasma cell myeloma.
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